MX2018011384A - Arn de replicacion en trans. - Google Patents
Arn de replicacion en trans.Info
- Publication number
- MX2018011384A MX2018011384A MX2018011384A MX2018011384A MX2018011384A MX 2018011384 A MX2018011384 A MX 2018011384A MX 2018011384 A MX2018011384 A MX 2018011384A MX 2018011384 A MX2018011384 A MX 2018011384A MX 2018011384 A MX2018011384 A MX 2018011384A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- rna
- protein
- alphavirus
- trans
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000014616 translation Effects 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere en general a sistemas y métodos adecuados para la producción de proteínas de alto nivel. Aunque uno o más elementos de la presente invención se derivan de un alfavirus, la presente invención no requiere la propagación de partículas de virus. En particular, se prevé un sistema que comprende dos moléculas de ARN separadas, comprendiendo cada una una secuencia de nucleótidos derivada de un alfavirus: una molécula de ARN comprende una construcción de ARN para expresar la replicasa de alfavirus, y una molécula de ARN comprende un replicón de ARN que puede replicarse mediante la replicasa en trans. La construcción de ARN para expresar la replicasa de alfavirus comprende una caperuza 5'. De manera inesperada, se descubrió que la caperuza es adecuada para dirigir eficazmente la expresión de un transgén desde el replicón en trans. El sistema de la presente invención permite la expresión de una proteína de interés en una célula u organismo, pero no está asociado con la formación de partículas de virus no deseadas. Por lo tanto, la presente invención es adecuada para producir de manera eficiente y segura una proteína de interés, por ejemplo, una proteína terapéutica o una proteína antigénica, tal como una vacuna, en un organismo objetivo. En la presente se proporcionan métodos respectivos de producción de proteínas in vitro e in vivo, así como usos médicos. La presente invención también proporciona ADN que codifica las moléculas de ARN de la invención, y células que comprenden las moléculas de ARN de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/056160 WO2017162265A1 (en) | 2016-03-21 | 2016-03-21 | Trans-replicating rna |
| PCT/EP2017/055813 WO2017162461A1 (en) | 2016-03-21 | 2017-03-13 | Trans-replicating rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011384A true MX2018011384A (es) | 2019-02-13 |
Family
ID=55586324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011384A MX2018011384A (es) | 2016-03-21 | 2017-03-13 | Arn de replicacion en trans. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12338448B2 (es) |
| EP (2) | EP3964584A1 (es) |
| JP (2) | JP7105193B2 (es) |
| KR (1) | KR102441725B1 (es) |
| CN (2) | CN109328233B (es) |
| AU (1) | AU2017236240B2 (es) |
| BR (1) | BR112018068391A2 (es) |
| CY (1) | CY1124689T1 (es) |
| DK (1) | DK3433368T3 (es) |
| ES (1) | ES2896927T3 (es) |
| HR (1) | HRP20211715T1 (es) |
| HU (1) | HUE058889T2 (es) |
| IL (1) | IL261327B2 (es) |
| LT (1) | LT3433368T (es) |
| MA (1) | MA44479B1 (es) |
| MD (1) | MD3433368T2 (es) |
| MX (1) | MX2018011384A (es) |
| PL (1) | PL3433368T3 (es) |
| PT (1) | PT3433368T (es) |
| RS (1) | RS62543B1 (es) |
| RU (1) | RU2752580C2 (es) |
| SG (1) | SG11201807378SA (es) |
| SI (1) | SI3433368T1 (es) |
| SM (1) | SMT202100634T1 (es) |
| WO (2) | WO2017162265A1 (es) |
| ZA (2) | ZA201805520B (es) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (en) * | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| EP3681993A1 (en) * | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for reprogramming somatic cells |
| AU2018333530B2 (en) * | 2017-09-13 | 2024-05-30 | Biontech Cell & Gene Therapies Gmbh | RNA replicon for expressing a T cell receptor or an artificial T cell receptor |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| US10736957B2 (en) * | 2017-12-19 | 2020-08-11 | President And Fellows Of Harvard College | Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP3990648A1 (en) * | 2019-06-27 | 2022-05-04 | EMD Millipore Corporation | Cell expansion with self-replicating rna vectors expressing immortalization proteins |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| KR102462990B1 (ko) * | 2020-03-17 | 2022-11-07 | 에이비온 주식회사 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
| WO2022002783A1 (en) | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| GB202020061D0 (en) | 2020-12-17 | 2021-02-03 | Imp College Innovations Ltd | RNA construct |
| GB202020063D0 (en) | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| GB202020064D0 (en) | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| CN112852841A (zh) | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| US20240181038A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| JP2024518335A (ja) | 2021-04-26 | 2024-05-01 | アンスティチュ パスツール | ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 |
| WO2022234268A1 (en) * | 2021-05-04 | 2022-11-10 | Mogrify Limited | Cell conversion |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US12570977B2 (en) * | 2021-06-12 | 2026-03-10 | Mello Biotech Taiwan Co., Ltd. | mRNA composition and production method for use in anti-viral and anti-cancer vaccines |
| KR20240022610A (ko) | 2021-06-18 | 2024-02-20 | 사노피 | 다가 인플루엔자 백신 |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| CN115960922A (zh) * | 2021-10-09 | 2023-04-14 | 吴可行 | 自复制rna分子设计及其应用 |
| JP2024539089A (ja) | 2021-10-18 | 2024-10-28 | バイオエヌテック エスエー | 修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用 |
| WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4402150A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| US20240425541A1 (en) | 2021-10-22 | 2024-12-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4401788A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4402149A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| KR20240107146A (ko) | 2021-11-05 | 2024-07-08 | 사노피 | 호흡기 세포융합 바이러스 rna 백신 |
| WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
| CA3242439A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
| CA3256624A1 (en) | 2022-05-06 | 2023-11-09 | Sanofi | SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES |
| JP2025518221A (ja) | 2022-05-30 | 2025-06-12 | ビオンテック・ソシエタス・エウロパエア | 核酸の送達のための複合体 |
| CA3265295A1 (en) | 2022-08-22 | 2024-02-29 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CORONAVIRUS VACCINES |
| JP2025532191A (ja) | 2022-09-26 | 2025-09-29 | ビオンテック・ソシエタス・エウロパエア | 核酸複合体及びその使用 |
| WO2024086549A1 (en) * | 2022-10-17 | 2024-04-25 | The University Of North Carolina At Chapel Hill | Chimeric alphaviruses for directed evolution |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4605010A1 (en) | 2022-10-21 | 2025-08-27 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024094881A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Respiratory syncytial virus rna vaccination |
| US12115217B2 (en) | 2022-11-18 | 2024-10-15 | Trustees Of Boston University | Self-replicating RNA and uses thereof |
| JP2025541298A (ja) | 2022-12-15 | 2025-12-18 | サノフィ パスツール インコーポレイテッド | ｍＲＮＡ組換えキャッピング酵素 |
| CN120456919A (zh) | 2022-12-19 | 2025-08-08 | 葛兰素史克生物有限公司 | 乙型肝炎组合物 |
| WO2024133550A1 (en) | 2022-12-22 | 2024-06-27 | Vector Biopharma Ag | Eukaryotic self-amplifying system |
| WO2024176192A1 (en) | 2023-02-24 | 2024-08-29 | BioNTech SE | Immunogenic compositions |
| WO2024180262A1 (en) | 2023-03-02 | 2024-09-06 | Sanofi | Compositions for use in treatment of chlamydia |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| IL324411A (en) | 2023-05-05 | 2026-01-01 | Sanofi Pasteur Inc | Preparations for use in the treatment of acne |
| WO2024231565A1 (en) | 2023-05-10 | 2024-11-14 | Sanofi | Combination respiratory mrna vaccines |
| WO2024236192A1 (en) | 2023-05-17 | 2024-11-21 | Institut Pasteur | Heterodimer of poxvirus a16 and g9 proteins as an immunogen |
| EP4474015A1 (en) | 2023-06-05 | 2024-12-11 | Veterna Srl | Noda-like rna-vaccine pharmacon and production and uses thereof |
| WO2025017202A2 (en) | 2023-07-19 | 2025-01-23 | Sanofi | Porphyromonas gingivalis antigenic constructs |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| TW202519509A (zh) | 2023-08-01 | 2025-05-16 | 德商拜恩技術股份公司 | 可離子化硫脂質及其用途 |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025084729A1 (ko) * | 2023-10-16 | 2025-04-24 | 한국생명공학연구원 | 단백질 번역 효율 향상용 RNA 구조체, 이를 포함하는 mRNA 구조체 및 이의 용도 |
| WO2025096982A1 (en) * | 2023-11-02 | 2025-05-08 | Amplitude Therapeutics, Inc. | Trans amplifying rnas comprising chemically modified nucleobases |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| TW202525287A (zh) | 2023-12-21 | 2025-07-01 | 德商拜恩技術運輸科技有限責任公司 | 可離子化脂質 |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025157249A1 (zh) * | 2024-01-24 | 2025-07-31 | 南京金斯瑞生物科技有限公司 | 一种自复制rna及其用途 |
| WO2025217136A2 (en) * | 2024-04-08 | 2025-10-16 | Amplitude Therapeutics, Inc. | Trans-amplifying rnas encoding immunomodulators |
| EP4656648A1 (en) | 2024-05-31 | 2025-12-03 | Consejo Superior De Investigaciones Científicas | Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof |
| WO2025262460A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Lipid compositions for nucleic acid delivery |
| WO2026008743A1 (en) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid |
| WO2026033380A1 (en) | 2024-08-05 | 2026-02-12 | BioNTech SE | Process for preparing oligosaccharide complexes |
| EP4696782A1 (en) | 2024-08-14 | 2026-02-18 | Starvax One B.V. | Improved split rna replicons |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010042069A (ko) * | 1998-03-20 | 2001-05-25 | 베니텍 오스트레일리아 리미티드 | 유전자 발현 조절방법 |
| WO2000053780A2 (en) | 1999-03-09 | 2000-09-14 | Large Scale Biology Corporation | Multiple component rna vector system for expression of foreign sequences |
| BR0113577A (pt) * | 2000-08-29 | 2004-07-06 | Wyeth Corp | Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo |
| JP4608210B2 (ja) * | 2001-05-31 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | キメラアルファウイルスレプリコン粒子 |
| US20030232324A1 (en) * | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| WO2003023026A1 (en) * | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003085114A1 (en) | 2002-04-01 | 2003-10-16 | Walter Reed Army Institute Of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| CN1791678A (zh) * | 2003-03-20 | 2006-06-21 | 阿尔法瓦克斯公司 | 改进的甲病毒复制子和辅助构建体 |
| JP4896021B2 (ja) * | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| DK2167523T3 (da) | 2007-06-19 | 2014-09-08 | Univ Louisiana State | Syntese og anvendelse af anti-reverse phosphorothioatanaloger af messenger-rna-cappen |
| NZ582495A (en) * | 2007-06-21 | 2012-05-25 | Alphavax Inc | Promoterless cassettes for expression of alphavirus structural proteins |
| WO2009024567A1 (en) | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Production method |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| RS54489B1 (sr) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk |
| DK2590676T3 (en) * | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
| HRP20221048T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
| SMT202200311T1 (it) | 2010-08-31 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Liposomi pegilati per somministrare rna codificante un immunogene |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP3456316A1 (en) | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| CN103781470A (zh) | 2011-07-06 | 2014-05-07 | 诺华股份有限公司 | 包含核酸的水包油乳液 |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| US20140255472A1 (en) | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| AU2012322704B2 (en) * | 2011-10-11 | 2017-09-07 | Novartis Ag | Recombinant self-replicating polycistronic RNA molecules |
| AU2012335277B2 (en) * | 2011-11-11 | 2018-06-14 | Variation Biotechnologies Inc. | Compositions and methods for treatment of cytomegalovirus |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| CN104220599A (zh) | 2012-03-27 | 2014-12-17 | 库瑞瓦格有限责任公司 | 人工核酸分子 |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| CA3075696A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Method of enhancing rna expression in a cell |
-
2016
- 2016-03-21 WO PCT/EP2016/056160 patent/WO2017162265A1/en not_active Ceased
-
2017
- 2017-03-13 MD MDE20190126T patent/MD3433368T2/ro unknown
- 2017-03-13 JP JP2018549306A patent/JP7105193B2/ja active Active
- 2017-03-13 MA MA44479A patent/MA44479B1/fr unknown
- 2017-03-13 RU RU2018131783A patent/RU2752580C2/ru active
- 2017-03-13 KR KR1020187027526A patent/KR102441725B1/ko active Active
- 2017-03-13 EP EP21200788.4A patent/EP3964584A1/en active Pending
- 2017-03-13 EP EP17710268.8A patent/EP3433368B1/en active Active
- 2017-03-13 CN CN201780018575.8A patent/CN109328233B/zh active Active
- 2017-03-13 ES ES17710268T patent/ES2896927T3/es active Active
- 2017-03-13 IL IL261327A patent/IL261327B2/en unknown
- 2017-03-13 HR HRP20211715TT patent/HRP20211715T1/hr unknown
- 2017-03-13 AU AU2017236240A patent/AU2017236240B2/en active Active
- 2017-03-13 BR BR112018068391A patent/BR112018068391A2/pt not_active Application Discontinuation
- 2017-03-13 PT PT177102688T patent/PT3433368T/pt unknown
- 2017-03-13 DK DK17710268.8T patent/DK3433368T3/da active
- 2017-03-13 SI SI201730973T patent/SI3433368T1/sl unknown
- 2017-03-13 PL PL17710268T patent/PL3433368T3/pl unknown
- 2017-03-13 LT LTEPPCT/EP2017/055813T patent/LT3433368T/lt unknown
- 2017-03-13 MX MX2018011384A patent/MX2018011384A/es unknown
- 2017-03-13 SG SG11201807378SA patent/SG11201807378SA/en unknown
- 2017-03-13 WO PCT/EP2017/055813 patent/WO2017162461A1/en not_active Ceased
- 2017-03-13 SM SM20210634T patent/SMT202100634T1/it unknown
- 2017-03-13 US US16/086,127 patent/US12338448B2/en active Active
- 2017-03-13 HU HUE17710268A patent/HUE058889T2/hu unknown
- 2017-03-13 CN CN202211115420.5A patent/CN115386596A/zh not_active Withdrawn
- 2017-03-13 RS RS20211377A patent/RS62543B1/sr unknown
-
2018
- 2018-08-17 ZA ZA201805520A patent/ZA201805520B/en unknown
-
2019
- 2019-08-15 ZA ZA2019/05396A patent/ZA201905396B/en unknown
-
2021
- 2021-09-30 JP JP2021160491A patent/JP7421256B2/ja active Active
- 2021-11-03 CY CY20211100949T patent/CY1124689T1/el unknown
-
2025
- 2025-05-23 US US19/216,945 patent/US20250290095A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011384A (es) | Arn de replicacion en trans. | |
| MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
| MX2020010871A (es) | Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. | |
| CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
| MX2021000211A (es) | Metodos y productos para transfeccion de celulas. | |
| SG10201906673WA (en) | Artificial nucleic acid molecules | |
| PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
| MX2018011383A (es) | Replicon de arn para la expresion genica versatil y eficiente. | |
| WO2014172470A3 (en) | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal | |
| DOP2022000060A (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| EP4349854A3 (en) | Pd1-cd28 fusion proteins and their use in medicine | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| MX2019002345A (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| SG10201809146QA (en) | Recombinant host cell engineered to overexpress helper proteins | |
| MX2016009149A (es) | Variantes mejoradas de enzimas. | |
| RU2015143513A (ru) | Микровезикула и способ ее получения | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| AR100310A1 (es) | Moléculas para transporte de antígeno modular mejoradas y sus usos | |
| PH12019502442A1 (en) | Variants of human bmp7 protein | |
| WO2013046216A8 (en) | Two plasmid mammalian expression system | |
| PH12021550563A1 (en) | Pacas9 nuclease | |
| PE20250795A1 (es) | Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia | |
| HK1231917A1 (en) | Methods and products for nucleic acid production and delivery |